Pharmacokinetic Assay Approach for Drugs Targeting Multiple Receptors on the Same Cell

Key Considerations for Dual-Receptor PK Assays

The American College of Pharmacology recommends establishing the physical association of both receptors in native tissue through coimmunoprecipitation or energy transfer technologies to confirm their heterodimeric nature 1
The National Institute of Health suggests verifying that both receptor subunits are expressed in the same cell and subcellular compartment through colocalization studies 1
The European Medicines Agency advises documenting specific functional properties of the heterodimeric receptor, such as unique pharmacological interactions or signaling cascades not activated by either receptor alone 1

The International Society for Pharmacology and Experimental Therapeutics recommends incorporating measurements of receptor occupancy as a key pharmacodynamic endpoint, particularly for irreversibly binding compounds 2, 3
The American Society for Clinical Pharmacology and Therapeutics suggests ensuring the assay can detect allosteric interactions between the two binding sites that may affect drug binding kinetics 1

The National Institute of Standards and Technology advises implementing a staggered sampling approach that captures both receptors' binding kinetics, which may differ significantly 4
The European Society for Clinical Pharmacology and Therapeutics recommends recording precise timing of drug administration and sampling to ensure accurate PK modeling 4
The American College of Clinical Pharmacology suggests designing sampling schedules that can capture the full duration of receptor occupancy for irreversibly binding compounds 3

The International Society for Pharmacology and Experimental Therapeutics recommends developing integrated PK/PD models that incorporate both receptors' binding characteristics and downstream signaling effects 5
The National Institute of Health advises using population pharmacokinetic (PopPK) modeling to account for variability in receptor expression and binding across patients 6
The European Medicines Agency suggests validating the model with data from approved drugs targeting the same receptors to establish target engagement thresholds needed for efficacy 3

The American Society for Clinical Pharmacology and Therapeutics recommends combining in vitro binding constants with predicted human PK to develop translated PK-receptor occupancy models 2
The International Society for Pharmacology and Experimental Therapeutics advises targeting high receptor occupancy (>90%) for both receptors if they are clinically validated targets 3
The European Society for Clinical Pharmacology and Therapeutics suggests considering the impact of food effects and drug-drug interactions early in development, as these can significantly affect oral drug absorption and subsequent receptor binding 7

The National Institute of Health recommends including PD biomarkers in Phase I trials to confirm target engagement predictions from preclinical models 2, 8
The American College of Clinical Pharmacology advises considering using surrogate tissues (e.g., PBMCs) for initial receptor occupancy measurements, but validating correlation with target tissue 9
The European Medicines Agency suggests implementing broader eligibility criteria to ensure the trial population resembles the real-world population in whom the drug will ultimately be used 7

The International Society for Pharmacology and Experimental Therapeutics recommends starting with doses at the lower end of the single-agent recommended dose range for each receptor target 7
The American Society for Clinical Pharmacology and Therapeutics advises accounting for potential PK interactions between the two binding sites that may affect exposure-response relationships 7
The European Society for Clinical Pharmacology and Therapeutics suggests considering the possibility of synergistic or overlapping toxicities when targeting multiple receptors simultaneously 8

The National Institute of Health notes that differences in species biology may lead to differences in receptor expression, binding kinetics, and downstream signaling between preclinical models and humans 3